{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:50:34Z","timestamp":1780084234965,"version":"3.54.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and\/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration\u2013time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12248-025-01146-2","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:28:14Z","timestamp":1759778894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-1190","authenticated-orcid":false,"given":"Luna Prieto","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7102-9518","authenticated-orcid":false,"given":"P\u00e4r","family":"Nordell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0575-2295","authenticated-orcid":false,"given":"Christine","family":"Ahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-5184","authenticated-orcid":false,"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-6039","authenticated-orcid":false,"given":"Erik","family":"Sj\u00f6gren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1146_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJM198807073190105","volume":"319","author":"SM Grundy","year":"1988","unstructured":"Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24\u201333.","journal-title":"N Engl J Med"},{"key":"1146_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/343425a0","volume":"343","author":"JL Goldstein","year":"1990","unstructured":"Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425\u201330.","journal-title":"Nature"},{"key":"1146_CR3","unstructured":"(1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383\u20131389"},{"key":"1146_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0021-9150(98)00014-8","volume":"138","author":"JR Crouse 3rd","year":"1998","unstructured":"Crouse JR 3rd, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998;138:11\u201324.","journal-title":"Atherosclerosis"},{"key":"1146_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423.","journal-title":"BMJ"},{"key":"1146_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","volume":"35","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan CJ, Gotto AM Jr., Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"1146_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1146_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00002018-200022060-00003","volume":"22","author":"M Ucar","year":"2000","unstructured":"Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22:441\u201357.","journal-title":"Drug Saf"},{"key":"1146_CR9","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788\u201397.","journal-title":"Circulation"},{"key":"1146_CR10","doi-asserted-by":"publisher","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858\u201368.","journal-title":"Ann Intern Med"},{"key":"1146_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMc0908215","volume":"362","author":"A Echaniz-Laguna","year":"2010","unstructured":"Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010;362:564\u20135.","journal-title":"N Engl J Med"},{"key":"1146_CR12","first-page":"146","volume":"27","author":"A Holbrook","year":"2011","unstructured":"Holbrook A, Wright M, Sung M, Ribic C, Baker S. Statin-associated rhabdomyolysis: is there a dose-response relationship? Can J Cardiol. 2011;27:146\u201351.","journal-title":"Can J Cardiol"},{"key":"1146_CR13","doi-asserted-by":"publisher","unstructured":"Turner RM, Pirmohamed M (2019) Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9010022","DOI":"10.3390\/jcm9010022"},{"key":"1146_CR14","doi-asserted-by":"publisher","first-page":"e2217831120","DOI":"10.1073\/pnas.2217831120","volume":"120","author":"Y Yogev","year":"2023","unstructured":"Yogev Y, Shorer Z, Koifman A, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci U S A. 2023;120:e2217831120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1146_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96:470\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Group SC, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med. 2008;359:789\u201399.","journal-title":"N Engl J Med"},{"key":"1146_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16:809\u201322.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1146_CR18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/clpt.2012.163","volume":"92","author":"R Elsby","year":"2012","unstructured":"Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it\u2019s not just about OATP1B1. Clin Pharmacol Ther. 2012;92:584\u201398.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","volume":"106","author":"MJ Knauer","year":"2010","unstructured":"Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106:297\u2013306.","journal-title":"Circ Res"},{"key":"1146_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Collaboration GBDCKD","year":"2020","unstructured":"Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709\u201333.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1146_CR21","first-page":"S52","volume":"60","author":"PRV Malik","year":"2020","unstructured":"Malik PRV, Yeung CHT, Ismaeil S, Advani U, Djie S, Edginton AN. A physiological approach to pharmacokinetics in chronic kidney disease. J Clin Pharmacol. 2020;60(Suppl 1):S52-62.","journal-title":"J Clin Pharmacol"},{"key":"1146_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpt.757","volume":"102","author":"JO Miners","year":"2017","unstructured":"Miners JO, Yang X, Knights KM, Zhang L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clin Pharmacol Ther. 2017;102:436\u201349.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/phar.1347","volume":"34","author":"MS Joy","year":"2014","unstructured":"Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, Wang J, et al. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy. 2014;34:114\u201322.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1146_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.ajkd.2014.09.015","volume":"65","author":"BK Thomson","year":"2015","unstructured":"Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis. 2015;65(4):574\u201382.","journal-title":"Am J Kidney Dis"},{"key":"1146_CR25","doi-asserted-by":"publisher","unstructured":"Florens N, Calzada C, Lyasko E, Juillard L, Soulage CO (2016) Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins8120376.","DOI":"10.3390\/toxins8120376"},{"key":"1146_CR26","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/ki.1992.238","volume":"41","author":"T Shoji","year":"1992","unstructured":"Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992;41:1653\u201361.","journal-title":"Kidney Int"},{"key":"1146_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000321845","volume":"31","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189\u201396.","journal-title":"Blood Purif"},{"key":"1146_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1523-1755.2005.00166.x","volume":"67","author":"C Kim","year":"2005","unstructured":"Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028\u201332.","journal-title":"Kidney Int"},{"key":"1146_CR29","doi-asserted-by":"crossref","unstructured":"Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073\u20132081","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"1146_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2020.10.004","volume":"15","author":"GL Vega","year":"2021","unstructured":"Vega GL, Wang J, Grundy SM. Chronic kidney disease and statin eligibility. J Clin Lipidol. 2021;15:173\u201380.","journal-title":"J Clin Lipidol"},{"key":"1146_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/clpt.2010.81","volume":"88","author":"SR Allerheiligen","year":"2010","unstructured":"Allerheiligen SR. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther. 2010;88:135\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/psp4.12134","volume":"5","author":"L Kuepfer","year":"2016","unstructured":"Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, et al. Applied concepts in PBPK modeling: how to build a PBPK\/PD model. CPT Pharmacometrics Syst Pharmacol. 2016;5:516\u201331.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1146_CR33","unstructured":"Administration USF and D ZOCOR (simvastatin) Tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019766s085lbl.pdf."},{"key":"1146_CR34","unstructured":"Administration USF and D PRAVACHOL (pravastatin sodium) Tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/019898s062lbl.pdf."},{"key":"1146_CR35","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.csbj.2016.09.002","volume":"14","author":"VR Knight-Schrijver","year":"2016","unstructured":"Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, Le Novere N. The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J. 2016;14:363\u201370.","journal-title":"Comput Struct Biotechnol J"},{"key":"1146_CR36","unstructured":"(2021) PK-Sim and MoBI."},{"key":"1146_CR37","first-page":"1029","volume":"13","author":"L Prieto Garcia","year":"2024","unstructured":"Prieto Garcia L, Vildhede A, Nordell P, Ahlstr\u00f6m C, Montaser AB, Terasaki T, et al. Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins. CPT: Pharmacom Syst Pharmacol. 2024;13:1029\u201343.","journal-title":"CPT: Pharmacom Syst Pharmacol"},{"key":"1146_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S0090-9556(25)08889-0","volume":"19","author":"DW Everett","year":"1991","unstructured":"Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19:740\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1146_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2125.1990.tb03626.x","volume":"29","author":"SM Singhvi","year":"1990","unstructured":"Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990;29:239\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"1146_CR40","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1038\/psp.2014.47","volume":"3","author":"K Gadkar","year":"2014","unstructured":"Gadkar K, Budha N, Baruch A, Davis JD, Fielder P, Ramanujan S. A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations. CPT Pharmacometrics Syst Pharmacol. 2014;3:e149.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1146_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152\u201360.","journal-title":"Am J Cardiol"},{"key":"1146_CR42","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1002\/sim.4040","volume":"29","author":"T Stijnen","year":"2010","unstructured":"Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046\u201367.","journal-title":"Stat Med"},{"key":"1146_CR43","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1146_CR44","doi-asserted-by":"publisher","unstructured":"Schwarzer G R\u00fccker G. CJR (2015) Meta-Analysis with R. https:\/\/doi.org\/10.1007\/978-3-319-21416-0","DOI":"10.1007\/978-3-319-21416-0"},{"key":"1146_CR45","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/j.1552-4604.1992.tb03816.x","volume":"32","author":"CE Halstenson","year":"1992","unstructured":"Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol. 1992;32:124\u201332.","journal-title":"J Clin Pharmacol"},{"key":"1146_CR46","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.ASN.0000068461.45784.2F","volume":"14","author":"M Tonelli","year":"2003","unstructured":"Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC, Cholesterol, Recurrent Events Trial I. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"1146_CR47","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"1146_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/clpt.1990.136","volume":"48","author":"HY Pan","year":"1990","unstructured":"Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther. 1990;48:201\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR49","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/jcph.2043","volume":"62","author":"MA Butrovich","year":"2022","unstructured":"Butrovich MA, Tang W, Boulton DW, Nolin TD, Sharma P. Use of physiologically based pharmacokinetic modeling to evaluate the impact of chronic kidney disease on CYP3A4-mediated metabolism of saxagliptin. J Clin Pharmacol. 2022;62:1018\u201329.","journal-title":"J Clin Pharmacol"},{"key":"1146_CR50","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00228-014-1709-7","volume":"70","author":"KJ Barnes","year":"2014","unstructured":"Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097\u2013106.","journal-title":"Eur J Clin Pharmacol"},{"key":"1146_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2125.2004.02326.x","volume":"59","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. Br J Clin Pharmacol. 2005;59:479\u201382.","journal-title":"Br J Clin Pharmacol"},{"key":"1146_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1124\/dmd.114.062877","volume":"43","author":"G Margaillan","year":"2015","unstructured":"Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015;43:611\u20139.","journal-title":"Drug Metab Dispos"},{"key":"1146_CR53","doi-asserted-by":"publisher","unstructured":"Watanabe J, Kotani K, Gugliucci A. Paraoxonase 1 and chronic kidney disease: a meta-analysis. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12031199.","DOI":"10.3390\/jcm12031199"},{"key":"1146_CR54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/cpt.807","volume":"103","author":"M-L Tan","year":"2018","unstructured":"Tan M-L, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, et al. Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103:854\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cpt.1998","volume":"109","author":"DA Tatosian","year":"2020","unstructured":"Tatosian DA, Yee KL, Zhang Z, et al. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Clin Pharmacol Ther. 2020;109:403\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR56","doi-asserted-by":"publisher","unstructured":"Dong J, Prieto Garcia L, Huang Y, Tang W, Lundahl A, Elebring M, et al. Understanding statin-roxadustat drug-drug-disease interaction using physiologically-based pharmacokinetic modeling. Clin Pharmacol Ther. 2023. https:\/\/doi.org\/10.1002\/cpt.2980.","DOI":"10.1002\/cpt.2980"},{"key":"1146_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/dmd.107.018192","volume":"36","author":"J Naud","year":"2008","unstructured":"Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V. Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos. 2008;36:124\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1146_CR58","doi-asserted-by":"publisher","unstructured":"Takeda F, Oda M, Terasaki M, Kubota A, Asada K, Ichimura Y, et al. Downregulated expression of organic anion transporting polypeptide (Oatp) 2b1 in the small intestine of rats with acute kidney injury. Drug Metab Pharmacokinet. 2021. https:\/\/doi.org\/10.1016\/j.dmpk.2021.100411.","DOI":"10.1016\/j.dmpk.2021.100411"},{"key":"1146_CR59","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/cpt.1419","volume":"106","author":"A Bergman","year":"2019","unstructured":"Bergman A, Bi Y, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, et al. Effect of hepatic organic anion-transporting polypeptide 1B inhibition and chronic kidney disease on the pharmacokinetics of a liver-targeted glucokinase activator: a model-based evaluation. Clin Pharmacol Ther. 2019;106:792\u2013802.","journal-title":"Clin Pharmacol Ther"},{"key":"1146_CR60","doi-asserted-by":"crossref","unstructured":"Holzer B. Folkers G. Meier P. J. Fattinger K. SB. Differential regulation of basolateral and canalicular transporter expression in rat liver in chronic renal failure. Clin Pharmacol Ther 2005;77:34","DOI":"10.1016\/j.clpt.2004.12.023"},{"key":"1146_CR61","doi-asserted-by":"publisher","first-page":"F636","DOI":"10.1152\/ajprenal.2001.280.4.F636","volume":"280","author":"D Laouari","year":"2001","unstructured":"Laouari D, Yang R, Veau C, Blanke I, Friedlander G. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol. 2001;280:F636-45.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"1146_CR62","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1038\/psp.2014.24","volume":"3","author":"RH Rose","year":"2014","unstructured":"Rose RH, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M. Application of a physiologically based pharmacokinetic model to predict OATP1B1-related variability in pharmacodynamics of rosuvastatin. CPT Pharmacometrics Syst Pharmacol. 2014;3:e124.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"1146_CR63","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1038\/psp.2012.14","volume":"1","author":"J Lippert","year":"2012","unstructured":"Lippert J, Brosch M, von Kampen O, et al. A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol. 2012;1(11):e13.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1146_CR64","doi-asserted-by":"publisher","first-page":"e00007","DOI":"10.1002\/psp4.7","volume":"4","author":"C Pichardo-Almarza","year":"2015","unstructured":"Pichardo-Almarza C, Metcalf L, Finkelstein A, Diaz-Zuccarini V. Using a systems pharmacology approach to study the effect of statins on the early stage of atherosclerosis in humans. CPT Pharmacometrics Syst Pharmacol. 2015;4:e00007.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1146_CR65","doi-asserted-by":"publisher","first-page":"117762501771094","DOI":"10.1177\/1177625017710941","volume":"11","author":"JE Ming","year":"2017","unstructured":"Ming JE, Abrams RE, Bartlett DW, et al. A quantitative systems pharmacology platform to investigate the impact of Alirocumab and cholesterol-lowering therapies on lipid profiles and plaque characteristics. Gene Regul Syst Bio. 2017;11:1177625017710941.","journal-title":"Gene Regul Syst Bio"},{"key":"1146_CR66","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1194\/jlr.M092486","volume":"60","author":"V Sokolov","year":"2019","unstructured":"Sokolov V, Helmlinger G, Nilsson C, Zhudenkov K, Skrtic S, Hamren B, et al. Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia. J Lipid Res. 2019;60:1610\u201321.","journal-title":"J Lipid Res"},{"key":"1146_CR67","unstructured":"Agency EM ZOCORD (simvastatin) film-coated tablets. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/zocord-article-30-referral-annex-i-ii-iii_en.pdf."},{"key":"1146_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2165\/11596610-000000000-00000","volume":"35","author":"BY Reis","year":"2012","unstructured":"Reis BY, Olson KL, Tian L, Bohn RL, Brownstein JS, Park PJ, et al. A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis. Drug Saf. 2012;35:395\u2013406.","journal-title":"Drug Saf"},{"key":"1146_CR69","first-page":"1236","volume":"10","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Chiang CW, Wang L, Brock G, Milks MW, Cao W, et al. A multistate transition model for statin-induced myopathy and statin discontinuation. CPT: Pharmacometrics & Systems Pharmacology. 2021;10:1236\u201344.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"1146_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.jrn.2007.10.022","volume":"18","author":"JJ Carrero","year":"2008","unstructured":"Carrero JJ, Aguilera A, Stenvinkel P, Gil F, Selgas R, Lindholm B. Appetite disorders in uremia. J Ren Nutr. 2008;18:107\u201313.","journal-title":"J Ren Nutr"},{"key":"1146_CR71","doi-asserted-by":"publisher","unstructured":"Cupisti A, Gallieni M, Avesani CM, D\u2019Alessandro C, Carrero JJ, Piccoli GB. Medical nutritional therapy for patients with chronic kidney disease not on dialysis: the low protein diet as a medication. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113644.","DOI":"10.3390\/jcm9113644"},{"key":"1146_CR72","unstructured":"Services USD of H and H Eating Right for Chronic Kidney Disease. https:\/\/www.niddk.nih.gov\/health-information\/kidney-disease\/chronic-kidney-disease-ckd\/eating-nutrition."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01146-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:02:27Z","timestamp":1762196547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01146-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1146"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01146-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.P.G., P.N., and A.L. are employees and shareholders of AstraZeneca. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"154"}}